C. Goujard, M. Bonarek, L. Meyer, F. Bonnet, and M. Chaix, CD4 Cell Count and HIV DNA Level Are Independent Predictors of Disease Progression after Primary HIV Type 1 Infection in Untreated Patients, Clinical Infectious Diseases, vol.42, issue.5, pp.709-715, 2006.
DOI : 10.1086/500213

C. Rouzioux, J. Hubert, M. Burgard, C. Deveau, and C. Goujard, T Cell Counts, The Journal of Infectious Diseases, vol.192, issue.1, pp.46-55, 2005.
DOI : 10.1086/430610
URL : https://hal.archives-ouvertes.fr/pasteur-01420524

S. Lambert-niclot, P. Flandre, M. Valantin, G. Peytavin, and C. Duvivier, Factors Associated With Virological Failure in HIV-1???Infected Patients Receiving Darunavir/Ritonavir Monotherapy, The Journal of Infectious Diseases, vol.204, issue.8, pp.1211-1216, 2011.
DOI : 10.1093/infdis/jir518

Y. Yazdanpanah, C. Fagard, D. Descamps, A. Taburet, and C. Colin, High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment???Experienced Patients Infected with Multidrug???Resistant HIV: Results of the ANRS 139 TRIO Trial, Clinical Infectious Diseases, vol.49, issue.9, pp.1441-1449, 2009.
DOI : 10.1086/630210

C. Fagard, C. Colin, C. Charpentier, A. Rami, and C. Jacomet, Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.59, issue.5, pp.489-493, 2012.
DOI : 10.1097/QAI.0b013e31824bb720
URL : https://hal.archives-ouvertes.fr/hal-00875207

C. Charpentier, C. Piketty, D. Laureillard, P. Tisserand, and A. Si-mohamed, Dynamics of HIV-1 DNA level in highly antiretroviral-experienced patients receiving raltegravir-based therapy, European Journal of Clinical Microbiology & Infectious Diseases, vol.14, issue.2, pp.129-133, 2012.
DOI : 10.1097/00002030-200012220-00001

S. Reigadas, M. Andréola, L. Wittkop, O. Cosnefroy, and G. Anies, Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells, Journal of Antimicrobial Chemotherapy, vol.65, issue.3, pp.434-437, 2010.
DOI : 10.1093/jac/dkp473
URL : https://hal.archives-ouvertes.fr/hal-00522698

N. Ngo-giang-huong, C. Deveau, D. Silva, I. Pellegrin, I. Venet et al., Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy, AIDS, vol.15, issue.6, pp.665-673, 2001.
DOI : 10.1097/00002030-200104130-00001

L. Morand-joubert, F. Marcellin, O. Launay, S. Guiramand-hugon, and L. Gérard, Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081), J Acquir Immune Defic Syndr, vol.38, pp.268-276, 2005.

S. Yerly, T. Perneger, S. Vora, B. Hirschel, and L. Perrin, Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection, AIDS, vol.14, issue.18, pp.2805-2812, 2000.
DOI : 10.1097/00002030-200012220-00001

L. Rong and A. Perelson, Modeling Latently Infected Cell Activation: Viral and Latent Reservoir Persistence, and Viral Blips in HIV-infected Patients on Potent Therapy, PLoS Computational Biology, vol.354, issue.10, p.1000533, 2009.
DOI : 10.1371/journal.pcbi.1000533.t002

B. Ramratnam, J. Mittler, L. Zhang, D. Boden, and A. Hurley, The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy, Nature Medicine, vol.104, issue.1, pp.82-85, 2000.
DOI : 10.1038/9498